Skip Navigation


Annals of Oncology Advance Access originally published online on October 23, 2006
Annals of Oncology 2007 18(1):99-103; doi:10.1093/annonc/mdl323
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
18/1/99    most recent
mdl323v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in Ann Oncol
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (16)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by van Zandwijk, N
Right arrow Articles by Nederlof, P
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by van Zandwijk, N
Right arrow Articles by Nederlof, P
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2006 European Society for Medical Oncology

lung cancer

EGFR and KRAS mutations as criteria for treatment with tyrosine kinase inhibitors: retro- and prospective observations in non-small-cell lung cancer

N van Zandwijk1,*, A Mathy1, L Boerrigter2, H Ruijter2, I Tielen2, D de Jong2, P Baas1, S Burgers1 and P Nederlof2

1 Department of Thoracic Oncology
2 Department of Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands

* Correspondence to: Dr N. van Zandwijk, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands. Tel: +31-20-512-2958; Fax: +31-20-512-2572; E-mail: n.v.zandwijk{at}nki.nl

Results of individualized therapy guided by mutational tumor profile of patients with non-small-cell lung cancer are presented. After confirming the importance of epidermal growth factor receptor (EGFR) and KRAS mutations for (non)response on gefitinib in a retrospective series of patients, EGFR mutations were looked for before—and were a condition for—treatment with gefitinib or erlotinib. To increase the chance to find such a mutation, we selected patients on the basis of smoking status, gender and histopathology. Out of 41 patients selected, 13 (32%) were found to harbor an EGFR mutation. In nine of them it concerned deletions in exon 19 and in none of them KRAS mutations were detected. All nine patients with an exon 19 deletion had a favorable and continuing response to tyrosine kinase inhibitors (TKIs), while four other patients with point mutations responded less favorably: stable disease or a response of short duration. These observations confirm the potential role of EGFR and KRAS mutations in predicting (non)response to TKIs. Exon 19 deletions that are associated with the best responses might be used for first-line treatment selection, while KRAS mutations could play a role in excluding patients from treatment with TKIs.

Key words: EGFR mutation, erlotinib, gefitinib, KRAS mutation, NSCLC


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in Ann Oncol:

in this issue

Ann Oncol 2007 18: 1. [Extract] [FREE Full Text]  



This article has been cited by other articles:


Home page
 JCOHome page
U. McDermott and J. Settleman
Personalized Cancer Therapy With Selective Kinase Inhibitors: An Emerging Paradigm in Medical Oncology
J. Clin. Oncol., November 20, 2009; 27(33): 5650 - 5659.
[Abstract] [Full Text] [PDF]

Home page
 Anticancer ResHome page
M. PESEK, L. BENESOVA, B. BELSANOVA, P. MUKENSNABL, F. BRUHA, and M. MINARIK
Dominance of EGFR and Insignificant KRAS Mutations in Prediction of Tyrosine-kinase Therapy for NSCLC Patients Stratified by Tumor Subtype and Smoking Status
Anticancer Res, July 1, 2009; 29(7): 2767 - 2773.
[Abstract] [Full Text] [PDF]

Home page
 Proc Am Thorac SocHome page
G. J. Riely, J. Marks, and W. Pao
KRAS Mutations in Non-Small Cell Lung Cancer
Proceedings of the ATS, April 15, 2009; 6(2): 201 - 205.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
C.-H. Gow, Y.-L. Chang, Y.-C. Hsu, M.-F. Tsai, C.-T. Wu, C.-J. Yu, C.-H. Yang, Y.-C. Lee, P.-C. Yang, and J.-Y. Shih
Comparison of epidermal growth factor receptor mutations between primary and corresponding metastatic tumors in tyrosine kinase inhibitor-naive non-small-cell lung cancer
Ann. Onc., April 1, 2009; 20(4): 696 - 702.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
P. Laurent-Puig, A. Lievre, and H. Blons
Mutations and Response to Epidermal Growth Factor Receptor Inhibitors
Clin. Cancer Res., February 15, 2009; 15(4): 1133 - 1139.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
S.-G. Wu, Y.-L. Chang, Y.-C. Hsu, J.-Y. Wu, C.-H. Yang, C.-J. Yu, M.-F. Tsai, J.-Y. Shih, and P.-C. Yang
Good Response to Gefitinib in Lung Adenocarcinoma of Complex Epidermal Growth Factor Receptor (EGFR) Mutations with the Classical Mutation Pattern
Oncologist, December 1, 2008; 13(12): 1276 - 1284.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
C. S. Karapetis, S. Khambata-Ford, D. J. Jonker, C. J. O'Callaghan, D. Tu, N. C. Tebbutt, R. J. Simes, H. Chalchal, J. D. Shapiro, S. Robitaille, et al.
K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
N. Engl. J. Med., October 23, 2008; 359(17): 1757 - 1765.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
I. Kappers, H. M. Klomp, J. A. Burgers, N. Van Zandwijk, R. L.M. Haas, and R. van Pel
Neoadjuvant (Induction) Erlotinib Response in Stage IIIA Non-Small-Cell Lung Cancer
J. Clin. Oncol., September 1, 2008; 26(25): 4205 - 4207.
[Full Text] [PDF]

Home page
 Ann OncolHome page
G. D'Addario, D. Rauch, R. Stupp, M. Pless, R. Stahel, N. Mach, L. Jost, L. Widmer, C. Tapia, M. Bihl, et al.
Multicenter phase II trial of gefitinib first-line therapy followed by chemotherapy in advanced non-small-cell lung cancer (NSCLC): SAKK protocol 19/03
Ann. Onc., April 1, 2008; 19(4): 739 - 745.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
N van Zandwijk and M. van de Vijver
clairvoyance or reliable prediction of the future?
Ann. Onc., March 1, 2007; 18(3): 407 - 408.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.